Effective pharmacovigilance demands continuous monitoring of drug safety signals, a critical process that ensures accurate benefit-risk assessment while meeting global regulatory requirements. This paper examines
Written by Martin Holm-Petersen, Chief Strategy Officer Preamble This will be the first in a series of articles about the application of artificial intelligence (AI) and advanced
We are thrilled to share that Qinecsa’s Chief Strategy Officer, Martin Holm-Petersen, has been featured in IPI Journal’s article on the future of technology-led innovation
We are thrilled to share that Qinecsa’s Associate Vice President of Services Solutions, Dr Preeti Verma, has been featured in the latest edition of EPC
John Cogan has a degree in chemistry and could easily have become a scientist. However, he was always more fascinated by technology than the laboratory
Using our PV Design Studio, Reportum offers configurable forms tailored to your use cases and workflows, allowing you to capture data from all sources. With
Webinar: Revolutionizing Literature Screening Challenges, Innovations and Future Trends Join us for a focused and dynamic 30-minute webinar where our expert speaker dives into the
Qinecsa is thrilled to be exhibiting at the DIA EU, from March 18-20 2025 in Basel, Switzerland. DIA Europe 2025 will focus on sustainability, innovation
Industry Insights – Pharmaceutical Technology talks to Qinecsa Solutions‘ CEO, Adam Sherlock about the outlook for the Life Sciences industry in 2025, focusing in on
On The Agenda: Introduction Tackling Compliance and Global Challenges: Key regulatory requirements (e.g. EMA) and best practices – Strategies for addressing global surveillance complexities Next-
2 Leman Street,
London, E1W 9US
United Kingdom
Company number: 13916274
